Journal Article (Review Article) DZNE-2020-03092

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Olfactory dysfunction: common in later life and early warning of neurodegenerative disease.

 ;  ;  ;  ;

2013
Dt. Ärzte-Verl. Köln

Deutsches Ärzteblatt international 110(1-2), 1 - 7 () [10.3238/arztebl.2013.0001]

This record in other databases:    

Please use a persistent id in citations: doi:

Abstract: Disturbances of smell and taste are common. About 5% of the general population have anosmia (absence of the sense of smell). Olfactory dysfunction can markedly impair the quality of life.Review of pertinent literature retrieved by a selective search.In recent years, simple and reliable tests of the sense of smell have been introduced in otorhinolaryngology. Olfactory testing has become a new focus of attention in neurology as well, mainly because many patients with neurodegenerative diseases-including the majority of those with Parkinson's or Alzheimer's disease-have olfactory loss early on in the course of their disorder. Olfactory dysfunction is thus regarded as an early sign of neurodegenerative disease that may allow a tentative diagnosis to be made years before the motor or cognitive disturbances become evident. As for the treatment of olfactory loss, anti-inflammatory drugs and surgery can help in some cases, and olfactory training can lead to significant improvement of post-viral olfactory deficits.Olfactory dysfunction is common and becomes more common with advancing age. It is increasingly receiving attention as an important sign for the early diagnosis and the differential diagnosis of neurodegenerative disorders.

Keyword(s): Anti-Inflammatory Agents: therapeutic use (MeSH) ; Early Diagnosis (MeSH) ; Humans (MeSH) ; Neurodegenerative Diseases: diagnosis (MeSH) ; Neurodegenerative Diseases: etiology (MeSH) ; Olfaction Disorders: complications (MeSH) ; Olfaction Disorders: diagnosis (MeSH) ; Olfaction Disorders: therapy (MeSH) ; Risk Assessment (MeSH) ; Anti-Inflammatory Agents

Classification:

Contributing Institute(s):
  1. Parkinson's Disease Genetics AG Berg (AG Berg)
  2. Parkinson Genetics (AG Gasser 1)
Research Program(s):
  1. 345 - Population Studies and Genetics (POF3-345) (POF3-345)

Appears in the scientific report 2013
Database coverage:
Medline ; Clarivate Analytics Master Journal List ; IF < 5 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Document types > Articles > Journal Article
Institute Collections > TÜ DZNE > TÜ DZNE-AG Gasser
Public records
Publications Database
TÜ DZNE-AG Berg

 Record created 2020-02-18, last modified 2024-03-21


Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)